Ophthalmology
Maintaining leadership in the treatment of serious, vision-threatening diseases
Millions of people around the world are impacted by vision-threatening conditions, which can dramatically affect a person’s independence and quality of life. For example, the number of Americans with diabetic retinopathy, a diabetes complication that can lead to blindness, is expected to increase to more than 14 million by 2050 and is the leading cause of blindness among working-age adults.
Our commitment to researching retinal diseases
Regeneron’s scientific research has been focused on understanding how blocking the growth of new blood vessels can decrease the ability of fluid to pass through blood vessels in the eye. Our research has since brought fundamental change to the treatment paradigm for serious eye diseases.
Regeneron continues to advance our anti-angiogenesis expertise with potential new solutions for patients and eye care professionals. We are pursuing novel therapies for many other serious ophthalmic diseases, including geographic atrophy, glaucoma, uveitis and inherited retinal diseases. In addition to the proprietary Trap technology that was the basis for our leading therapeutic, we use many cutting-edge modalities such as monoclonal antibodies, RNA interference and gene therapy as the basis for new potential medicines.
Our Impact on Diseases of the Retina: Always Striving for Innovation
Regeneron’s unique impact on ophthalmology